Analysts Expect Aptinyx Inc (NASDAQ:APTX) Will Post Earnings of -$0.52 Per Share

Wall Street brokerages forecast that Aptinyx Inc (NASDAQ:APTX) will post earnings per share of ($0.52) for the current quarter, according to Zacks. Two analysts have made estimates for Aptinyx’s earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.57). Aptinyx posted earnings per share of ($1.83) in the same quarter last year, which suggests a positive year-over-year growth rate of 71.6%. The company is scheduled to announce its next quarterly earnings results before the market opens on Monday, August 12th.

On average, analysts expect that Aptinyx will report full-year earnings of ($2.15) per share for the current fiscal year, with EPS estimates ranging from ($2.25) to ($2.09). For the next financial year, analysts expect that the firm will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.31) to ($1.79). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Aptinyx.

Aptinyx (NASDAQ:APTX) last released its earnings results on Tuesday, May 14th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.04). The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $1.00 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%.

Several equities analysts recently weighed in on the company. ValuEngine upgraded Aptinyx from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research report on Tuesday, July 16th. Cantor Fitzgerald restated a “buy” rating on shares of Aptinyx in a research report on Tuesday, April 30th. Cowen restated a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. Finally, Svb Leerink began coverage on Aptinyx in a research report on Thursday, June 20th. They issued an “outperform” rating and a $12.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $12.71.

Several institutional investors have recently made changes to their positions in the company. Great West Life Assurance Co. Can purchased a new position in shares of Aptinyx in the fourth quarter valued at about $40,000. Barclays PLC lifted its position in shares of Aptinyx by 87.1% in the fourth quarter. Barclays PLC now owns 9,323 shares of the company’s stock valued at $154,000 after acquiring an additional 4,340 shares in the last quarter. Gabelli Funds LLC lifted its position in shares of Aptinyx by 45.9% in the second quarter. Gabelli Funds LLC now owns 15,901 shares of the company’s stock valued at $53,000 after acquiring an additional 5,000 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in shares of Aptinyx by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after acquiring an additional 5,652 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Aptinyx by 30.6% in the fourth quarter. Bank of New York Mellon Corp now owns 43,887 shares of the company’s stock valued at $726,000 after acquiring an additional 10,284 shares in the last quarter. Institutional investors and hedge funds own 58.40% of the company’s stock.

NASDAQ APTX traded up $0.10 on Monday, hitting $3.63. 168,760 shares of the company traded hands, compared to its average volume of 345,375. The firm has a market cap of $121.83 million, a P/E ratio of -1.38 and a beta of -0.03. The business has a 50 day simple moving average of $3.62. Aptinyx has a 52-week low of $2.88 and a 52-week high of $32.25.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Article: Swap

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.